A case report published in Cureus documents complete clearance of chronic plaque psoriasis with persistent facial involvement in a patient treated with risankizumab, an interleukin-23 inhibitor, after previous systemic therapies failed to clear facial lesions.

Chronic plaque psoriasis affecting the face remains one of the harder-to-treat presentations of the disease. Facial involvement occurs in a substantial share of psoriasis patients and carries disproportionate psychosocial burden, yet many conventional systemic agents deliver inconsistent facial clearance. The report adds to a growing body of single-case and small-cohort literature examining whether IL-23 blockade offers an advantage in this specific clinical scenario.

Risankizumab targets the p19 subunit of IL-23, upstream of the TH17 pathway that drives psoriatic inflammation. The agent has established efficacy in moderate-to-severe plaque psoriasis in its pivotal trials, but published data specifically addressing facial involvement remain limited, and case-level documentation fills a real gap for clinicians weighing options for patients whose facial disease persists on other regimens.

In the reported case, the patient's chronic plaque disease had proved resistant to prior treatments, with facial lesions persisting despite the therapies used before the switch. Following initiation of risankizumab at its standard dosing, the patient achieved clearance of facial involvement, and the treatment was tolerated without the report noting significant adverse events.

The authors position the outcome as support for considering risankizumab when facial plaque psoriasis fails to respond adequately to other systemic options. As with any single-patient report, the evidence class is modest: no control arm, no standardized PASI or facial-specific scoring trajectory comparable across a cohort, and the inherent possibility of regression to the mean or observer bias. What the case does provide is a documented, reproducible clinical observation that aligns with the drug's mechanism and its trial-level performance in broader plaque disease.

For dermatologists, the practical takeaway is narrower than a trial result but still useful. Patients with visible, treatment-recalcitrant facial plaque psoriasis represent a persistent unmet need, and the case suggests IL-23 p19 inhibition is a reasonable escalation when facial lesions linger on existing therapy. Clinicians will still want to counsel patients on the limits of case-report evidence and anchor expectations to the agent's broader trial data.

The report's authors call for larger, prospectively designed studies with facial-specific outcome measures to confirm the signal. Whether risankizumab's facial efficacy holds up in controlled cohorts — and how it compares head-to-head with IL-17 inhibitors, which also carry facial-psoriasis data — remains an open question that future comparative work should address.